Development · 3 Oct 2026

Aurobindo Pharma Limited announced on Saturday that it received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Perampanel tablets in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg.

2 publishers have reported this development. Each act of reporting is below, cited.

The record

cnbctv18.com3 Oct 2026

Aurobindo Pharma has received final approval from the US FDA to manufacture and market Perampanel tablets in multiple strengths, including 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg.

zeebiz.com3 Oct 2026

Aurobindo Pharma

₹1,676.80

▲ +0.29%

Close (EOD), as of 1 Oct 2026 · source

Aurobindo Pharma: results, dividends, orders, the full cited record →

More on Aurobindo Pharma

Aurobindo Pharma acquired Lannett, a US-based complex generics and controlled substances manufacturer, for approximately $250 million funded by internal accruals.

3 Oct 2026 · 1 publisher

US pharma tariff relief has different implications for Indian drugmakers depending on whether their US business is built around patented medicines, generics, complex injectables or contract manufacturing.

2 Oct 2026 · 1 publisher

Pharma stocks are picking up pace, with the sector continuing to show a strong overall technical setup despite the possibility of short-term profit booking.

2 Oct 2026 · 1 publisher

Aurobindo’s arm, Acrotech Biopharma, launches Adquey in US - The HinduBusinessLine ... market and expands the company ... s commercial presence ... Acrotech Biopharma, a subsidiary of Aurobindo Pharma, has launched Adquey in the U.S.

2 Oct 2026 · 2 publishers

Aurobindo Pharma announced that it has received final approval to manufacture and market beclomethasone dipropionate hfa inhalation aerosol in the US.

17 Sep 2026 · 5 publishers

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.